Trials / Unknown
UnknownNCT03792724
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label, phase I-II study to evaluate the safety and activity of intratumoral urelumab combined with systemic nivolumab in patients with advanced solid tumors. Serial tumor and blood samples will be obtained during the study to characterize the changes induced by treatment in the tumor microenvironment, as well as predictive biomarkers of response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Urelumab + Nivolumab | Treatment with intratumoral urelumab after which Nivolumab will be given. |
Timeline
- Start date
- 2019-01-30
- Primary completion
- 2023-01-30
- Completion
- 2023-01-30
- First posted
- 2019-01-03
- Last updated
- 2019-01-03
Locations
2 sites across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03792724. Inclusion in this directory is not an endorsement.